Created at	Source	Raw Value	Validated value
June 25, 2024, noon	usa	* receipt of a sars-cov-2 (covid-19) vaccine after enrollment into tico. participants who received a sars-cov-2 vaccine prior to enrollment in tico may be enrolled in this study. * known allergy to any component of the study eligible vaccine(s).	* receipt of a sars-cov-2 (covid-19) vaccine after enrollment into tico. participants who received a sars-cov-2 vaccine prior to enrollment in tico may be enrolled in this study. * known allergy to any component of the study eligible vaccine(s).
July 21, 2021, 4 p.m.	usa	receipt of a sars-cov-2 (covid-19) vaccine after enrollment into tico. participants who received a sars-cov-2 vaccine prior to enrollment in tico may be enrolled in this study. known allergy to any component of the study eligible vaccine(s).	receipt of a sars-cov-2 (covid-19) vaccine after enrollment into tico. participants who received a sars-cov-2 vaccine prior to enrollment in tico may be enrolled in this study. known allergy to any component of the study eligible vaccine(s).